Cullinan Therapeutics (NASDAQ:CGEM) Downgraded by Wall Street Zen to Sell

Posted by Geri Gentry on Aug 2nd, 2026

Wall Street Zen cut shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) from a hold rating to a sell rating in a report released on Saturday.

CGEM has been the topic of a number of other research reports. BTIG Research upped their target price on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Wednesday, July 8th. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Cullinan Therapeutics in a research note on Thursday, June 11th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday, June 8th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.14.

View Our Latest Report on CGEM

Cullinan Therapeutics Stock Down 5.8%

CGEM stock opened at $16.50 on Friday. Cullinan Therapeutics has a 52-week low of $5.68 and a 52-week high of $19.43. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -4.91 and a beta of -0.01. The business has a fifty day moving average of $16.38 and a two-hundred day moving average of $14.57.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.09. As a group, sell-side analysts anticipate that Cullinan Therapeutics will post -3.06 EPS for the current year.

Insider Transactions at Cullinan Therapeutics

In related news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $17.82, for a total transaction of $142,560.00. Following the transaction, the insider owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. This represents a 4.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Trading of Cullinan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its position in shares of Cullinan Therapeutics by 49.2% during the first quarter. Bank of America Corp DE now owns 516,724 shares of the company’s stock worth $7,343,000 after purchasing an additional 170,417 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Cullinan Therapeutics by 160.6% in the first quarter. Royal Bank of Canada now owns 4,044 shares of the company’s stock valued at $58,000 after purchasing an additional 2,492 shares in the last quarter. Elmind Capital LP grew its holdings in shares of Cullinan Therapeutics by 71.0% in the first quarter. Elmind Capital LP now owns 530,000 shares of the company’s stock valued at $7,531,000 after purchasing an additional 220,000 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Cullinan Therapeutics by 347.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 75,310 shares of the company’s stock worth $1,070,000 after buying an additional 58,488 shares during the period. Finally, Quantinno Capital Management LP increased its stake in Cullinan Therapeutics by 50.6% during the 1st quarter. Quantinno Capital Management LP now owns 72,282 shares of the company’s stock worth $1,027,000 after buying an additional 24,281 shares during the period. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.